Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10359413 | 1.00 | CYP1A2 (0.62) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| SCHEMBL7891041 | 1.00 | CYP1A2 (0.62) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| Bromide SCHEMBL27620628 | 0.98 | CYP1A2 (0.60) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| SCHEMBL24837421 | 0.98 | CYP1A2 (0.66) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| SCHEMBL21591048 | 0.93 | — | — | |
| SCHEMBL236633 | 0.93 | — | — | |
| SCHEMBL4065310 | 0.93 | — | — | |
| SCHEMBL12535509 | 0.88 | CYP1A2 (0.58) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 | |
| SCHEMBL13014945 | 0.86 | CYP1A2 (0.56) | CYP1A2ADRA2AALDH1A1CHRM1 | |
| SCHEMBL2017584 | 0.82 | CYP1A2 (0.67) | CYP1A2ADRA2AALDH1A1CHRM1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117751004-A | Carbon dioxide capture system | 氢涞新能源科技(美国)公司 | 2024-03-22 | — | — | CN | claimed |
| WO-2023014710-A1 | CARBON DIOXIDE CAPTURE SYSTEM | DIOXIDE MATERIALS, INC. (US) | 2023-02-09 | — | — | WO | claimed |
| US-11511259-B1 | Carbon dioxide capture system | DIOXIDE MATERIALS, INC. (US) | 2022-11-29 | — | — | US | claimed |
| EP-3166710-A1 | ABSORBENT SYSTEM AND METHOD FOR CAPTURING CO2 FROM GAS STREAM | Sintef TTO AS (NO) | 2017-05-17 | — | — | EP | claimed |
| US-20170106331-A1 | ABSORBENT SYSTEM AND METHOD FOR CAPTURING CO2 FROM A GAS STREAM | SINTEF TTO AS (NO) | 2017-04-20 | — | — | US | claimed |
| WO-2015190936-A1 | ABSORBENT SYSTEM AND METHOD FOR CAPTURING CO2 FROM GAS STREAM | SINTEF TTO AS (NO) | 2015-12-17 | — | — | WO | claimed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | claimed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | claimed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| JP-53044573-A | — | — | None | — | — | JP | disclosed |
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250201841-A1 | ELECTRODE SLURRY FOR ELECTROCHEMICAL ENERGY STORAGE DEVICE | POLYBATT MATERIAL CO., LTD. (TW) | 2025-06-19 | — | — | US | disclosed |
| EP-0031910-B1 | ANILINE DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESSES FOR THEIR PRODUCTION | MERCK PATENT GmbH (DE) | 1983-04-13 | — | — | EP | disclosed |
| EP-0031910-A1 | Aniline derivatives, pharmaceutical preparations containing them and processes for their production | MERCK PATENT GmbH (DE) | 1981-07-15 | — | — | EP | disclosed |
| US-4130510-A | Curing of epoxy resin systems using halfester compounds containing aliphatic tertiary amino groups | HITACHI CHEMICAL CO., LTD. (JP) | 1978-12-19 | — | — | US | disclosed |
| US-4096196-A | Diazotization-fluorination in a medium of hydrogen fluoride containing tertiary amine compounds | OLIN CORPORATION (US) | 1978-06-20 | — | — | US | disclosed |
| JP-S5344573-A | OPTICAL ACTIVE 2-PIPERIDINEETHANOLS AND THEIR PREPARATION | TEIJIN LTD | 1978-04-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | CYP1A2 2158/4885ADRA2A 1179/4885ALDH1A1 1848/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | CYP1A2 1309/4885ADRA2A 2543/4885ALDH1A1 619/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | CYP1A2 3754/4885ADRA2A 3666/4885ALDH1A1 984/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | CYP1A2 337/4885ADRA2A 1238/4885ALDH1A1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.